OCREVUS Drug Profile

Summary for Tradename: OCREVUS

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for OCREVUS

Recent Clinical Trials for OCREVUS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amgen	PHASE3
Autoimmunity Centers of Excellence (ACE)	Phase 4
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4

See all OCREVUS clinical trials

Pharmacology for OCREVUS

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody
Chemical Structure	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OCREVUS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OCREVUS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for OCREVUS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2036-12-20	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2035-01-08	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2035-11-05	Patent claims search

Market Dynamics and Financial Trajectory for OCREVUS

Last updated: February 19, 2026

What is OCREVUS's current market position?

Ocrevus (ocrelizumab) is a monoclonal antibody developed by Roche. It targets CD20-positive B cells, approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Launch in 2017 positioned it as a leading biologic in MS treatments.

Market share and sales data:

Year	Global Sales (USD millions)	Market Share (MS biologics)
2017	710	14%
2020	2,350	18%
2022	2,900	20%

In 2022, Roche reported Ocrevus sales of approximately USD 2.9 billion, representing a 23% increase over 2021. It remains the top-selling MS biologic, surpassing competitors like Novartis's Kesimpta and Biogen's Tecfidera.

What are the key drivers of OCREVUS's revenue growth?

Primary factors include:

• Expanding indications: Approval for primary progressive MS (PPMS) in 2017 widened the addressable patient base.
• Persistent prevalence: MS affects approximately 2.8 million globally, with increasing diagnosis rates.
• Treatment persistence: Ocrevus has demonstrated favorable efficacy and tolerability, leading to high patient persistence.
• Pricing strategy: Average wholesale price (AWP) in the US hovers around USD 70,000 annually, with some discounts and rebates.

How does OCREVUS compare with competitors?

Drug	Company	Approved Indications	Launch Year	2022 Sales (USD millions)	Market Share in MS biologics (%)
Ocrevus	Roche	RMS, PPMS	2017	2,900	20
Kesimpta	Novartis	RMS	2018	640	4.4
Mavenclad	Merck	RMS, PPMS	2017	520	3.6
Tysabri	Biogen	RMS, PPMS	2004	1,100	7.6

Ocrevus holds the largest market share among biologic treatments for MS, driven by its efficacy data and expanded approvals.

What are the regulatory and pipeline prospects influencing future sales?

Key regulatory milestones:

• FDA approval for PPMS in 2017.
• EU approval for PPMS in 2018.
• Ongoing phase 3 trials for other autoimmune indications, including neuromyelitis optica spectrum disorder (NMOSD).

Pipeline developments:

• Ocrevus is under evaluation for other autoimmune conditions such as rheumatoid arthritis and lupus.
• Potential for label expansion in pediatric MS, pending trial results.

What market risks could affect OCREVUS's revenue trajectory?

• Patent expiry: Patent protections last until 2028 in key markets. Patent cliffs could allow biosimilar competition.
• Biosimilar emergence: Several biosimilars for rituximab (the reference molecule) in development could exert pricing and volume pressure.
• Competitive innovations: Oral and small-molecule therapies like Novartis's Mayzent (siponimod) and Biogen's Tecfidera could threaten MS biologic dominance.
• Pricing and reimbursement policies: Increasing scrutiny and cost-containment measures may restrict pricing power, especially outside the US.

How might future market dynamics shape OCREVUS's financial profile?

• Growth in MS prevalence: Rising MS diagnosis rates in emerging markets can expand revenue.
• Access improvements: Broader insurance coverage and national healthcare programs will influence sales.
• Pricing strategies: Roche might adjust list prices or expand patient access through negotiated discounts.
• Pipeline success: Approval for additional indications and label expansions could boost sales.

What are the financial outlooks for OCREVUS over the next five years?

Analysts project:

Year	Estimated Global Sales (USD millions)	CAGR (2023-2027)	Primary Growth Drivers
2023	3,200	10%	New indications, market expansion
2024	3,520	10%	Increased access, competitive stabilization
2025	3,850	9.3%	Pipeline approvals
2026	4,200	9.1%	Patent expiration strategies, biosimilar competition
2027	4,600	9.5%	Mature market penetration, pipeline contributions

Key Takeaways

• Ocrevus remains a dominant biologic MS therapy with USD 2.9 billion in 2022 sales.
• Growth is driven by expanded indications, high patient persistence, and ongoing market penetration.
• Patent expirations in 2028, biosimilar threats, and competitive innovations pose risks.
• Future sales will depend on pipeline success, access expansion, and pricing strategies.

FAQs

1. When will OCREVUS face biosimilar competition?
   B iosimilar versions of rituximab are under development, with potential approvals around 2025-2027, depending on regulatory pathways.

2. How does OCREVUS's efficacy compare with oral MS therapies?
   Ocrevus has demonstrated higher efficacy in reducing relapse rates and slowing disability progression compared to some oral options, but adherence differs.

3. What are implications of expanding into other autoimmune indications?
   Label expansions could significantly increase revenue, but success depends on clinical trial outcomes and regulatory approvals.

4. Will regulatory changes affect OCREVUS pricing?
   Potentially. Health authorities in Europe and Asia are increasingly focusing on drug pricing, which could impact margins.

5. What are the prospects for OCREVUS outside of MS?
   Trials for diseases such as rheumatoid arthritis and NMO are ongoing; success could diversify revenue streams.

---

References

[1] Roche. (2022). Ocrevus (ocrelizumab) Sales Data. Roche Annual Report.
[2] Global Data. (2022). Multiple sclerosis therapeutics market report.
[3] FDA. (2017). Ocrevus approval letter.
[4] EMA. (2018). Ocrevus approval for primary progressive multiple sclerosis.
[5] Statista. (2022). Multiple sclerosis prevalence worldwide.